BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 9171998)

  • 1. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
    Balázs M; Carroll P; Kerschmann R; Sauter G; Waldman FM
    Genes Chromosomes Cancer; 1997 Jun; 19(2):84-9. PubMed ID: 9171998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene.
    Wiest JS; Franklin WA; Otstot JT; Forbey K; Varella-Garcia M; Rao K; Drabkin H; Gemmill R; Ahrent S; Sidransky D; Saccomanno G; Fountain JW; Anderson MW
    Cancer Res; 1997 Jan; 57(1):1-6. PubMed ID: 8988029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
    J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
    Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
    J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
    Yoshida S; Todoroki T; Ichikawa Y; Hanai S; Suzuki H; Hori M; Fukao K; Miwa M; Uchida K
    Cancer Res; 1995 Jul; 55(13):2756-60. PubMed ID: 7796400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased p16 levels correlate with pRb alterations in human urothelial cells.
    Yeager T; Stadler W; Belair C; Puthenveettil J; Olopade O; Reznikoff C
    Cancer Res; 1995 Feb; 55(3):493-7. PubMed ID: 7834615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
    Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
    Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell cycle regulators in bladder cancer: relationship to schistosomiasis.
    Eissa S; Ahmed MI; Said H; Zaghlool A; El-Ahmady O
    IUBMB Life; 2004 Sep; 56(9):557-64. PubMed ID: 15590562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization.
    Dreyling MH; Bohlander SK; Adeyanju MO; Olopade OI
    Cancer Res; 1995 Mar; 55(5):984-8. PubMed ID: 7867008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
    Farrell WE; Simpson DJ; Bicknell JE; Talbot AJ; Bates AS; Clayton RN
    Cancer Res; 1997 Jul; 57(13):2703-9. PubMed ID: 9205080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
    Herman JG; Merlo A; Mao L; Lapidus RG; Issa JP; Davidson NE; Sidransky D; Baylin SB
    Cancer Res; 1995 Oct; 55(20):4525-30. PubMed ID: 7553621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
    Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
    Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer.
    Tsutsumi M; Tsai YC; Gonzalgo ML; Nichols PW; Jones PA
    Oncogene; 1998 Dec; 17(23):3021-7. PubMed ID: 9881704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
    Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES
    Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in molecular mechanisms of leukemogenesis: the cyclin-dependent kinase 4-inhibitor gene in human leukemias.
    Hirai H; Ogawa S; Hangaishi A; Takahashi T; Kurokawa M; Mitani K; Ueda R; Yazaki Y
    Leukemia; 1997 Apr; 11 Suppl 3():358-60. PubMed ID: 9209389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
    Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
    Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.
    Xu L; Sgroi D; Sterner CJ; Beauchamp RL; Pinney DM; Keel S; Ueki K; Rutter JL; Buckler AJ; Louis DN
    Cancer Res; 1994 Oct; 54(20):5262-4. PubMed ID: 7923151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
    Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
    Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
    Flores JF; Walker GJ; Glendening JM; Haluska FG; Castresana JS; Rubio MP; Pastorfide GC; Boyer LA; Kao WH; Bulyk ML; Barnhill RL; Hayward NK; Housman DE; Fountain JW
    Cancer Res; 1996 Nov; 56(21):5023-32. PubMed ID: 8895759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
    Brenner AJ; Aldaz CM
    Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.